The Complex Role of Herpesviruses in Increasing Alzheimer’s Disease Risk

Alzheimer’s disease (AD) is widely recognised for its defining features: amyloid-beta plaques and tangles of hyperphosphorylated tau protein (p-tau). But what if infections, particularly by herpes simplex virus 1 (HSV-1), played a pivotal role in sparking these hallmark pathologies? New research from the University of Pittsburgh School of Medicine and the Hebrew University of Jerusalem has shed new light on this possibility, uncovering how HSV-1 interacts with tau protein to impact neuronal survival.

The Role of HSV-1 in AD Pathology

Published in Cell Reports by Dr. Vanesa R. Hyde and her team, the study explores how HSV-1 infection increases tau phosphorylation through the cGAS-STING-TBK1 immune pathway. Interestingly, this process—while often associated with neurodegeneration—appears to serve an antiviral function. Phosphorylated tau reduces the expression of HSV-1 proteins and boosts neuronal viability. As Dr. Hyde explains, “This study demonstrates that tau phosphorylation, typically viewed as toxic, can act as a protective response in the presence of viral infections.”

The researchers used advanced imaging techniques like decrowding expansion pathology (dExPath) to map the interactions between HSV-1 proteins and p-tau in human brain samples. They found that as Alzheimer’s progressed, HSV-1 proteins strongly colocalized with p-tau but not amyloid-beta plaques. These findings suggest that tau phosphorylation may be a cellular defence mechanism against HSV-1, distinct from other AD pathologies.

Implications for Alzheimer’s Research

This study challenges traditional views of tau protein solely as a contributor to neurodegeneration. Instead, it proposes that p-tau plays a dual role: offering short-term neuroprotection during viral infections but potentially causing harm if chronically activated. This sheds light on why infections, particularly HSV-1, have been linked to a higher risk of dementia. For example, a Taiwanese study showed that untreated HSV-1 infections increased the risk of developing Alzheimer’s by 2.56 times, but antiviral treatment significantly reduced this risk.

By linking tau pathology to the innate immune response, the research underscores the importance of targeting the cGAS-STING pathway in future therapeutic strategies. Drugs that fine-tune this pathway could potentially limit chronic tau hyperphosphorylation while preserving its antiviral benefits.

A New Chapter in Alzheimer’s Research

The findings also reignite interest in the infectious theory of Alzheimer’s, which has been debated for decades. Beyond HSV-1, other pathogens like Epstein-Barr and varicella zoster viruses have been implicated in neurodegenerative diseases. This highlights the need to explore how infections interact with brain immune responses, contributing to diseases like AD.

The potential for innovative treatments grows as we deepen our understanding of these mechanisms. Targeting the immune pathways that mediate the tau-virus interplay could revolutionize how we approach Alzheimer’s disease and other neurodegenerative conditions.

This study provides a crucial step in connecting the dots between infections and Alzheimer’s, offering a fresh perspective on a complex disease that affects millions worldwide.